Adrien Sipos

Adrien Sipos, M.D., Ph.D., has been appointed as Interim Chief Medical Officer. Prior to joining Q32 Bio, Dr. Sipos served as President and Chief Medical Officer at PRAXICO Inc. Before PRAXICO, Dr. Sipos was Head of Immunology, Late-Stage Clinical Development at Biogen, Inc. Earlier, Dr. Sipos held clinical development and medical affairs roles at Sanofi Genzyme and Eli Lilly. Dr. Sipos completed postdoctoral research at the University of Oxford and received a Ph.D. in Clinical Immunology from the Hungarian Academy of Sciences. She received an M.D. and completed her medical residency at Debrecen Medical University. Dr. Sipos is a member of the Beth Israel Deaconess Medical Center's Institutional Biosafety Committee.